Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations

Sai-Hong Ignatius Ou; Huamao M Lin; Jin-Liern Hong; Yu Yin; Shu Jin; Jianchang Lin; Minal Mehta; Danny Nguyen; Joel W Neal

doi:10.1016/j.jtocrr.2023.100558

Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations

JTO Clin Res Rep. 2023 Aug 16;4(10):100558. doi: 10.1016/j.jtocrr.2023.100558. eCollection 2023 Oct.

Authors

Sai-Hong Ignatius Ou¹, Huamao M Lin², Jin-Liern Hong², Yu Yin³, Shu Jin⁴, Jianchang Lin³, Minal Mehta⁴, Danny Nguyen⁵, Joel W Neal⁶

Affiliations

¹ Division of Hematology-Medical Oncology, Department of Internal Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California.
² Global Evidence and Outcomes Oncology, Takeda Development Center Americas, Inc., Lexington, Massachusetts.
³ Oncology Statistics, Takeda Pharmaceuticals United States, Inc., Lexington, Massachusetts.
⁴ Clinical Science, Oncology, Takeda Development Center Americas, Inc., Lexington, Massachusetts.
⁵ Oncology and Hematology, City of Hope National Medical Center, Duarte, California.
⁶ Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, California.

Abstract

Introduction: This study describes treatment patterns and outcomes in patients with NSCLC with EGFR exon 20 insertions (EGFRex20ins) in the United States.

Methods: The Flatiron Health electronic health record database was used to select three cohorts among patients diagnosed with NSCLC with EGFRex20ins (January 1, 2011-February 29, 2020): (1) first-line (1L) or patients receiving 1L therapy after documented EGFRex20ins; (2) second or later-line (≥2L) or patients receiving ≥2L therapy after documented EGFRex20ins; and (3) ≥2L postplatinum trial-aligned, or ≥2L patients previously treated with platinum chemotherapy whose baseline characteristics aligned with key eligibility criteria (initiating new treatment after documented EGFRex20ins and ≥1 previous treatment excluding mobocertinib or amivantamab) of the mobocertinib trial NCT02716116. Real-world end points were confirmed overall response rate, overall survival, and progression-free survival.

Results: Of 237 patients with EGFRex20ins-mutated NSCLC, 129 and 114 patients were included in the 1L and ≥2L cohorts, respectively. In 1L patients, platinum chemotherapy plus nonplatinum chemotherapy (31.0%) and EGFR tyrosine kinase inhibitors (28.7%) were the most common regimens. In ≥2L patients, immuno-oncology monotherapy (28.1%) and EGFR tyrosine kinase inhibitors (17.5%) were the most common index treatments. For any 1L, ≥2L, and ≥2L postplatinum trial-aligned patients, the confirmed overall response rate was 18.6%, 9.6%, and 14.0%, respectively; the median overall survival was 17.0, 13.6, and 11.5 months; the median progression-free survival was 5.2, 3.7, and 3.3 months, respectively.

Conclusions: The outcomes for patients with NSCLC with EGFRex20ins were poor. This real-world study provides a benchmark on treatment outcomes in this patient population and highlights the unmet need for improved therapeutic options.

Keywords: Chemotherapy; EGFR exon 20 insertions; Immunotherapy; Non–small cell lung cancer; Treatment outcome; Tyrosine kinase inhibitor therapy.